Bovie Medical Corporation is actively engaged in the business of manufacturing and marketing a variety of electrosurgical medical products as well as developing related technologies and products.  Recently, greater effort and resources have been directed towards manufacturing electrosurgical generators which are primarily used for outpatient surgical procedures.  Bovie continues the ongoing development of high-powered generators for operating room use.  It is estimated that the electrosurgery industry is currently growing 10% annually and is used in 80% of all surgical procedures performed worldwide.

	John Aneralla Buttonwood Advisory Group, Inc. 15705 Framingham Lane Huntersville, NC 28078 Toll Free Phone: (800) 940-9087
	Bovie Medical Corporation Reports 9.4 Percent Increase in First Quarter Revenues: Reports Positive Results in J-Plasma™ Surgeries May 15, 2012   Bovie Medical Corporation Announces 2011 Year End Financial Results and Reports on J-PLASMA™ Progress March 29, 2012   Bovie Medical Corporation Receives 510 K Clearances to Market Patented J-PLASMA™ Technology February 01, 2012   Bovie Medical Board of Directors Announces Decision on Inquiry Regarding COO's Bio November 29, 2011   Bovie Medical Corporation Adds to its J-Plasma™ Patent Prortfolio November 21, 2011   Bovie Medical Corporation Announces Third Quarter Financial Results November 14, 2011   More news releases
	Coming Soon
	See more about Bovie Corp. stock

• Revenues for the quarter ended September 30, 2011 were $6.3 million
  versus $6.5 million for the comparable period last year, resulting in net
  income of $63,000 or $.00 per diluted share compared to net income of
  $9,000 or $.00 per share in the same period last year.
  
  
• Revenues for the nine months ended September 30, 2011 increased 7% to
  $19.3 million versus $18.0 million for the comparable period last year. Net income was $984,000 or $.06 per diluted share compared to a net loss of $(166,000) or $(.01) per share in the same period last year.
  
  
• Received patents for laparoscopic electrosurgical electrical leakage detection device and a method of performing endoscopic or laparoscopic surgery with
  an electrosurgical device that generates a plasma stream (J-Plasma™).
  
  
• Bovie received a $2.6 million commitment from an OEM customer to
  manufacture electrosurgical generators with delivery slated to begin later
  in the year.
   
• Signed an exclusive agreement with Medical Illumination, Inc. to distribute
  next generation of medical lighting.
  
  
• Applied for 510(k) clearance with the FDA to market its J-Plasma™
  handpiece with retractable cutting features in both laparoscopic and
  open configurations. The newly developed device will offer soft tissue
  coagulation and/or tissue cutting with and without simultaneously applied
  J-Plasma™ energy. On November 8, 2010 Bovie filed additional patents for
  its new J-Plasma™ handpiece.
  

The Company’s products compete primarily in the multi-billion dollar market for electrosurgical generators and single-use specialty medical products. Industry demand for electrosurgical medical products is being favorably impacted by several trends including: the aging population, increased emphasis on less invasive surgical procedures, higher level of outpatient care, continuing pressure to improve productivity and reduce costs; and the heightened awareness for reducing the transmission of infectious diseases.

J-Plasma ICON GS electrosurgical generator - Approximate total worldwide market exceeds $2 billion 
The technology utilizes a gas ionization process producing a stable thin beam of ionized gas that can be controlled in a wide range of temperatures and intensities, providing the surgeon great precision, minimal invasiveness and an absence of conductive currents during surgery. Potential markets include gynecology, urology, dermatology, plastic surgery, neurology, gastroenterology, and veterinary medicine. Bovie anticipates directing its resources to each individual niche as best suited to the Company's overall business plan.

Vessel Sealing Instruments - Approximate worldwide market $1 billion
The patent pending vessel sealing instruments allow for monopolar and bipolar energy combined with intelligent feedback from an electrosurgical generator. The vessel sealing instrument handle will accommodate a wide array of possible applications in either monopolar or bipolar surgeries serving the endoscopic needs. The Endoscopy market is the fastest growing market in electrosurgery. The vessel sealing instruments are subject to FDA 510k clearance to market.

Standard Electrosurgical Generators & accessories - Approximate worldwide $80 million
Standard electrosurgical generators range in power from 30-300 watts and are used in physician offices, surgery centers and hospitals. Bovie holds a dominate market position in physician offices for these products and a growing market share in surgery centers and hospitals.

Battery Operated Cauteries - Approximate worldwide market $10 million

Battery operated cauteries represent the Company's original line. Cauteries were originally designed for precise hemostasis (to stop bleeding) in ophthalmology. The Company estimates it manufactures more types of cauteries than any other company in the world controlling up to 70% of the market, including a line of replaceable battery and tip cauteries, which are popular in overseas markets.

This corporate information sheet is intended to provide general information about the Company. It is not designed to be a source for making investment decisions, and Bovie will make every reasonable effort to include accurate and current information. Except for the historical information contained herein, this information may include forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those projected. More complete information is contained in the company's SEC filings. Neither Bovie Medical Corporation nor any party involved in creating, producing or delivering this information sheet shall be liable for any direct, incidental, consequential, indirect, or punitive damages arising out of the user's access, use, or liability to use the corporate information sheet, or any errors or omissions in the content.